Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nelivaptan in Generalized Anxiety Disorder
NCT00374166Phase 2Completed
- Sponsor
- Sanofi
- Start
- Aug 2006
- Primary completion
- Feb 2008
- Modality
- Allosteric Modulators, Orthosteric Ligands, Irreversible Covalent Inhibitors
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of nelivaptan in generalized anxiety disorder (GAD) (4 arms), sponsored by Sanofi. Primary endpoint: Hamilton Anxiety Rating Scale at 8 weeks. Started Aug 2006; status: completed.
02
Drugs
nelivaptan
03
Conditions
generalized anxiety disorder (GAD)
Beyond the preview
Go deeper on NCT00374166.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00374166.